Tag Archives: neovascular

Efficacy The Vascular Endothelial Growth Factor Inhibition Study in Ocular Neovascularization (VISION) trial showed that 70% of patients with wet AMD treated for 12 months with six-weekly pegaptanib sodium responded to treatment (lost <15 letters). This compared with only 55% of control (sham) subjects. Furthermore, 6% of patients receiving pegaptanib experienced an improvement in their vision (gained ≥15 letters).2 In a retrospective analysis performed to acquire data on ‘real-life’ experience with pegaptanib, data were collected from 164 patients with any angiographic subtype of sub-foveal choroidal neovascularisation secondary to